CLSA Capital Partners’ ARIA V invests in ACT Genomics, a leading DNA sequencing-based cancer solution provider in Asia

Hong Kong – Wednesday, 26 September 2018: ARIA Investment Partners V, LP and ARIA Investment Partners V (Non-US), LP (collectively as “ARIA V”) is pleased to announce it has become a co-lead investor in ACT Genomics’ (“ACTG” or the “Company”) latest round of capital raising.

This is the first investment by ARIA V, the recently launched fifth generation pan-Asia private equity fund managed and advised by CLSA Capital Partners (“CLSACP”). For more than two decades, ARIA Funds have tracked the dynamic consumption patterns shaped by demographic and socioeconomic trends across Asia.

ACTG is Asia’s leading DNA sequencing-based cancer solution provider. The Company’s mission is to provide cancer patients personalised genomic information-based treatment plans using a Next Generation Sequencing (“NGS”) platform, an Asian genome database, leading professional bioinformatics and biomedical teams, medical reports, and integrated services.

ACTG’s flagship NGS panel, ACTOnco, investigates 440 cancer-related genes by incorporating a signaling pathway design. ACTOnco provides optimal treatment suggestions to clinicians, including targeted therapies, hormonal therapies, chemotherapies, and immunotherapies, for all solid tumour types.

Managing Director of the ARIA Funds, Miranda Tang, commented: “This is the first investment made in precision medicine and companion diagnostics by ARIA Funds. DNA sequencing is a critical component in assisting cancer patients to identify personalised treatment solutions and we are optimistic about its future growth prospects. ACTG is regarded as a leading player in this space and we are very excited to partner with them. The ARIA V investment will help to strengthen the Company’s footprint and capabilities across Asia and further accelerate its strategic plan.”

Dr. Hua Chien Chen, Co-Founder and CEO of ACTG, said: “ACTG will continue its business expansion including the establishment of additional NGS laboratories accredited by the College of American Pathologists in Hong Kong, new product research and development, expansion of clinical services operations in Asia, and drug development collaboration with global and regional bio-pharmaceutical companies.”

Currently, ACTG has operations in Hong Kong, Japan, Singapore and Taiwan. In addition, the Company has established a joint venture with Canon Medical System Corporation in Japan to operate cancer genomic profiling services and sequencing data analysis covering Japan.

– end –

About ACT Genomics
Founded in 2014, ACTG provides optimal cancer treatment plans, cancer relapse and drug resistance monitoring as well as cancer risk assessment and immunotherapy evaluation through DNA sequencing-based technology. The Company achieves precise cancer genetic variants detection with minimum tumour samples, and delivers to every cancer patient personalised genomic, information-based treatment plans through a cutting-edge NGS platform, medical reports and integrated services. ACTG also provides comprehensive data analysis on cancer genomics applying Artificial Intelligence and integrates genomic databases with Asia specific genome profiling.

ACTG’s comprehensive portfolio received the 2017 Asia Pacific Molecular Diagnostics Product Line Strategy Leadership Award by Frost & Sullivan.

For more information, visit www.clsacapital.com.  For more information about CLSA visit www.clsa.com.